Company intelligence / Profile preview

Vision RT

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

Vision RT’s SGRT solutions are in active clinical use at over 3,000 sites worldwide—including most of the top US cancer centers. Peer-reviewed studies show their AlignRT system can reduce treatment times by an average of 22% per fraction and improve accuracy compared to physical surrogates. Their DoseRT product enables real-time dose visualization using Cherenkov imaging to detect delivery errors in up to ~10% of patients studied.

Therapeutic areas: Oncology
Modalities: Device (Surface Guided Radiation Therapy systems)Non-pharmacological therapy (patient positioning and monitoring technology)Imaging technology (Cherenkov imaging integration)
Industry: Medical Imaging

Partnerships

GenesisCare (global strategic partnership for SGRT rollout across their network)RaySearch Laboratories (integration with RayStation treatment planning software)

Beyond the preview

Go deeper on Vision RT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vision RT.

Explore the full profile